Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010;27(5):371-417.
doi: 10.1615/critrevtherdrugcarriersyst.v27.i5.10.

Cancer chemotherapy with lipid-based nanocarriers

Affiliations
Review

Cancer chemotherapy with lipid-based nanocarriers

Donghua Liu et al. Crit Rev Ther Drug Carrier Syst. 2010.

Abstract

Nanotechnology has a profound effect on many areas of scientific research. Having grown exponentially, the focus of nanotechnology has been on therapeutic activity, such as cancer treatment. Lipid-based nanocarriers have attracted increasing scientific and commercial attention in the last few years as alternative carriers for the delivery of anticancer drugs. Lipid-based nanocarriers have played significant roles in the formulation of anticancer drugs to improve therapeutics. Shortcomings frequently encountered with anticancer compounds, such as poor solubility, normal tissue toxicity, poor specificity and stability, as well as the high incidence rate of drug resistance, are expected to be overcome through use of lipid-based nanocarriers. In this review, the advantages and methods of using nanocarriers to improve cancer treatment efficiency will be discussed. In addition, types of lipid-based nanocarriers are presented and hotspots in research are highlighted. It is anticipated that, in the near future, lipid-based nanocarriers will be further improved to deliver cytotoxic anticancer compounds in a more efficient, specific and safe manner.

PubMed Disclaimer

Similar articles

Cited by

Publication types

LinkOut - more resources